The potential of BRAF-targeted therapy combined with immunotherapy in melanoma

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Metastatic melanoma treatment options include immune checkpoint inhibitors and BRAF-targeted therapy.
• The optimal sequencing or combination of these therapies for BRAFV600-mutated melanoma remains unclear.
• Emerging clinical trial data are providing insights into combined treatment approaches.

Purpose of the Study:

• To review the preclinical and clinical rationale for combining BRAF-targeted therapy with immunotherapy.
• To discuss the effects of BRAF-targeted therapy on the tumor immune microenvironment.
• To summarize clinical trial data on combination therapies for metastatic melanoma.

Main Methods:

• Literature review of preclinical studies and clinical trials.
• Analysis of data on BRAF-targeted therapy's impact on the tumor microenvironment.
• Synthesis of findings from clinical trials investigating combination therapies.

Main Results:

• BRAF-targeted therapy demonstrates high response rates in metastatic melanoma.
• BRAF-targeted therapy alters the tumor microenvironment, potentially enhancing sensitivity to immunotherapy.
• Early clinical trials combining BRAF-targeted therapy with anti-PD-1/PD-L1 agents are encouraging.

Conclusions:

• Combination therapy with BRAF-targeted agents and immunotherapy is a promising strategy for metastatic melanoma.
• Further data from ongoing randomized clinical trials are necessary to establish definitive clinical practice guidelines.
• The findings suggest potential benefits for select patients with BRAFV600-mutated melanoma.